{
    "2019-12-31": [
        [
            {
                "time": "2019-12-31",
                "original_text": "公告精选：沃森生物13价肺炎球菌多糖结合疫苗获批上市；宝能受让长安PSA 50%股权",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "13价肺炎球菌多糖结合疫苗",
                        "获批上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "沃森生物收购上海泽润13.04%股权",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "上海泽润",
                        "股权收购"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "首个国产13价肺炎疫苗获批上市，挑战辉瑞“利润奶牛”",
                "features": {
                    "keywords": [
                        "国产13价肺炎疫苗",
                        "获批上市",
                        "辉瑞"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "首个国产13价肺炎结合疫苗获批上市，价格低于进口疫苗，距正式接种还需3个月以上",
                "features": {
                    "keywords": [
                        "国产13价肺炎结合疫苗",
                        "获批上市",
                        "价格优势"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "沃森生物：13价肺炎球菌多糖结合疫苗上市注册申请获批",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "13价肺炎球菌多糖结合疫苗",
                        "上市注册申请获批"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "沃森生物(300142.SZ)：中保嘉沃及一致行动人减持1537.44万股 持股比例降至5%以下 减持股份",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "中保嘉沃",
                        "减持股份"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "沃森生物：中保嘉沃不再是公司持股5%以上股东",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "中保嘉沃",
                        "持股5%以上股东"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "全球第二款！中国自主研发十三价肺炎结合疫苗获批上市",
                "features": {
                    "keywords": [
                        "十三价肺炎结合疫苗",
                        "自主研发",
                        "获批上市"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "供不应求，规模超千亿！疫苗产业链分析（附流感概念）",
                "features": {
                    "keywords": [
                        "疫苗产业链",
                        "供不应求",
                        "规模超千亿"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "2019年12月疫苗批签发数据跟踪月报",
                "features": {
                    "keywords": [
                        "疫苗批签发数据",
                        "跟踪月报"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "国产13价肺炎疫苗上市在即，或与辉瑞正面“单挑”",
                "features": {
                    "keywords": [
                        "国产13价肺炎疫苗",
                        "辉瑞",
                        "正面竞争"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "医药行业深度报告：疫苗2020-丰收之年,高光时刻",
                "features": {
                    "keywords": [
                        "医药行业",
                        "疫苗",
                        "2020-丰收之年"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-12-31",
                "original_text": "沃森生物(300142.SZ)拟斥5亿元参设健康产业投资基金",
                "features": {
                    "keywords": [
                        "沃森生物",
                        "健康产业投资基金",
                        "5亿元"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}